Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging
Glypican-3 (GPC3), the cellular membrane proteoglycan, has been established as a tumor biomarker for early diagnosis of hepatocellular carcinoma (HCC). GPC3 is highly expressed in more than 70% HCC tissues detected by antibody-based histopathological systems. Recently, aptamers, a short single-stran...
Main Authors: | Lili Dong, Hongxin Zhou, Menglong Zhao, Xinghui Gao, Yang Liu, Dongli Liu, Wei Guo, Hongwei Hu, Qian Xie, Jia Fan, Jiang Lin, Weizhong Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-12-01
|
Series: | Molecular Therapy: Nucleic Acids |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253118302579 |
Similar Items
-
Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma
by: Youshi Zheng, et al.
Published: (2023-09-01) -
SITE-613
by: Poag, C, et al.
Published: (1987) -
Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer
by: Jun Young Park, et al.
Published: (2020-10-01) -
Structure based innovative approach to analyze aptaprobe–GPC3 complexes in hepatocellular carcinoma
by: Woo-Ri Shin, et al.
Published: (2022-04-01) -
SYNTHESIS OF BASE MODIFIED PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES AS INHIBITORS OF HIV-1
by: Kemal, O, et al.
Published: (1991)